Exane Derivatives Emergent Bio Solutions Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, Exane Derivatives holds 39 shares of EBS stock, worth $369. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39
Previous 1,245
96.87%
Holding current value
$369
Previous $51,000
98.04%
% of portfolio
0.0%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding EBS
# of Institutions
159Shares Held
33.7MCall Options Held
453KPut Options Held
931K-
Black Rock Inc. New York, NY3.84MShares$36.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.4MShares$32.2 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.49MShares$23.6 Million0.03% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA2.22MShares$21.1 Million0.0% of portfolio
-
State Street Corp Boston, MA1.91MShares$18.1 Million0.0% of portfolio
About Emergent BioSolutions Inc.
- Ticker EBS
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 49,861,500
- Market Cap $473M
- Description
- Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...